ASPC Announces Official Program Covering the ABCs of Preventive Cardiology at Premier Annual Congress on CVD Prevention

JACKSONVILLE, Fla. – The American Society for Preventive Cardiology (ASPC) announces the official program for the ASPC 2022 Congress on CVD Prevention, scheduled July 29-31, 2022 in Louisville, KY. The program covers the “ABCs of Preventive Cardiology” over the 2.5 day live, in-person program, and can be found on aspconline.org/2022congress. Included in the 2022 program…

Read More

Jardiance® phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease

OXFORD, United Kingdom and RIDGEFIELD, Conn. and INDIANAPOLIS, March 16, 2022 /PRNewswire/ — The EMPA-KIDNEY trial, evaluating the effect of Jardiance® (empagliflozin) in adults with chronic kidney disease (CKD), will stop early based on a recommendation from the trial’s Independent Data Monitoring Committee. This follows a formal interim assessment that met prespecified criteria for positive efficacy, announced the Medical Research Council (MRC) Population…

Read More

REGENERON AND ULTRAGENYX COLLABORATE TO COMMERCIALIZE EVKEEZA® (EVINACUMAB) OUTSIDE THE UNITED STATES

Evkeeza is a first-in-class medicine approved by the U.S. Food and Drug Administration (FDA) and European Commission (EC) to treat an ultra-rare inherited form of high cholesterol TARRYTOWN, N.Y. and NOVATO, Calif., Jan. 7, 2022 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Ultragenyx Pharmaceutical Inc. today announced a license and collaboration agreement for Ultragenyx to clinically develop, commercialize and distribute Evkeeza® (evinacumab)…

Read More

FDA Approval of LEQVIO(R) (inclisiran)

Novartis has announced that LEQVIO® (inclisiran) has been approved by the FDA for patients with atherosclerotic cardiovascular disease (ASCVD) who need to further lower their bad cholesterol, despite being on a maximally tolerated statin. If interested, the LEQVIO full prescribing information can be found here: https://www.novartis.us/sites/www.novartis.us/files/leqvio.pdf Novartis is committed to continuing their work with the…

Read More